Colchicine/Strong CYP3A4 Inhibitors Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your intestine and liver process colchicine.
What might happen:
The amount of colchicine in your blood may increase and cause toxic side effects. Deaths have been reported.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together or if you have taken your other medicine in the previous 14 days. Make sure your doctor knows if you have any kidney or liver problems, which may make the interaction worse. Your doctor may need to change your medicine or the dose of your colchicine. Let your doctor know right away if you have any unexplained muscle weakness or pain, numbness or tingling in the fingers or toes; unusual bleeding or bruising; abdominal pain; nausea; severe diarrhea or vomiting; feeling weak or tired; increased infections; or pale or gray color of the lips, tongue, or palms of hands.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Colcrys (colchicine) US prescribing information. AR Scientific, Inc. July, 2011.
- 2.Anonymous. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPati entsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174315. htm July 30, 2009.
- 3.Ketek (telithromycin) US prescribing information. Sanofi-Aventis U.S. LLC November, 2015.
- 4.van der Velden W, Huussen J, Ter Laak H, de Sevaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med 2008 May;66(5):204-6.
- 5.Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol 2006 Jul-Aug;19(4):515-7.
- 6.Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P. Acute colchicine intoxication during clarithromycin administration. Ann Pharmacother 2004 Dec;38(12):2074-7.
- 7.Cheng VC, Ho PL, Yuen KY. Two probable cases of serious drug interaction between clarithromycin and colchicine. South Med J 2005 Aug;98(8):811-3.
- 8.Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C. Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration. Clin Nephrol 2001 Feb;55(2):181-2.
- 9.Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK, Cheung BM, Yuen KY. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005 Aug 1;41(3):291-300.
- 10.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and -drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 11.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company March, 2018.
- 12.Prezista (darunavir) US prescribing information. Tibotec Inc. May, 2019. 13.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. September, 2016.
- 13.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories August, 2019.
- 14.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. September, 2016.
- 15.Norvir (ritonavir) US prescribing information. Abbott Laboratories August, 2019.
- 16.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. March, 2019.
- 17.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2018.
- 18.Victrelis (boceprevir) US prescribing information. Schering Corporation January, 2017.
- 19.Incivek (telaprevir) US prescribing information. Vertex Pharmaceuticals Incorporated October, 2013.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.